VPS34 Inhibitor Compounds for Proliferative Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective inhibitors for Vacuolar Protein Sorting 34 (VPS34), a critical enzyme involved in autophagy and various cellular processes, which are essential for treating proliferative, inflammatory, and cardiovascular disorders.
Innovation Solution
Development of novel compounds that inhibit VPS34, specifically designed to target and block its activity, thereby modulating signaling cascades and degradation pathways associated with these disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then existing treatment options are available, but effective VPS34 inhibition is lacking
Solution Approach 1:
The patent segments the VPS34 inhibition problem by developing a series of compounds with different structural variations (formula I with varying R1, R2, R3, R4, R5, L1, L2, L3 groups) to target specific aspects of VPS34 activity, allowing selective optimization for different therapeutic applications
Solution Approach 2:
The patent applies parameter changes by systematically modifying chemical structure parameters (substituents, linkers, ring structures) of the inhibitor compounds to optimize their binding affinity, selectivity, and pharmacological properties for effective VPS34 inhibition
2Object-affected harmful factors
If VPS34 activity is inhibited, then abnormal cellular activities are disrupted, but therapeutic properties must be optimized
Solution Approach 1:
The patent incorporates feedback mechanisms through biological assays and cellular models to evaluate VPS34 inhibition effects, allowing iterative optimization of compound structures based on observed therapeutic outcomes and side effect profiles
Solution Approach 2:
The patent optimizes therapeutic properties by adjusting chemical parameters of the inhibitor compounds to achieve optimal balance between potency, selectivity, pharmacokinetics, and safety profile for clinical application
Data Source
AI summary
The present invention provides a compound of formula I:wherein R1, X1, X2, R2, R3, R4, R5, n, and m are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.